Utility of PFA-100® closure time vs. optical aggregometry in assessing the efficacy of platelet membrane glycoprotein IIb/IIIa antagonists in vitro

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1542-1548

  Stegnar, Mojca ^a   Božič, Mojca ^a   Dolenc, Marija Sollner ^b   Anderluh, Petra Štefanič ^b   Kikelj, Danijel ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Closure time; Glycoprotein IIb IIIa antagonist; Peptidomimetic; Platelet aggregation; Platelet function analyser

Indexed keywords

2 AMINO N[4 (4 CARBAMIMIDOYLBENZYL) 3 OXO 3,4 DIHYDRO 2H BENZO[B][1,4]OXAZIN 7 YL] 3 PHENYLPROPANAMIDE; 3 [7 (4 CARBAMIMIDOYLBENZAMIDO) 2 OXO 5 PHENYL 2,3 DIHYDRO 1HBENZO[E][1,4]DIAZEPIN 3 YL]PROPANOIC ACID TRIFLUOROACETATE; 4 [5 (4 CARBAMIMIDOYLPHENYL) 1,2,4 OXADIAZOL 3 YL]BENZOIC ACID HYDROCHLORIDE; 5 [7 (4 CARBAMIMIDOYLBENZAMIDO) 3 OXO 2,3 DIHYDROBENZO[B][1,4]OXAZIN 4 YL]PENTANOIC ACID ACETATE; ADENOSINE DIPHOSPHATE; ADRENALIN; ARGINYLGLYCYLASPARTYLSERINE; COLLAGEN; DKT 59; DPS 172; EPTIFIBATIDE; ETHYL 3 [4 [N [2 (4 CARBAMIMIDOYLBENZYLAMINO) 2 OXOETHYL]ACETAMIDO]BENZAMIDO] 2 (4 METHYLPHENYLSULFONAMIDO)PROPANOATE ACETATE; ETHYL 5 [7 (4 CARBAMIMIDOYLBENZAMIDO) 3 OXO 2,3 DIHYDROBENZO[B][1,4]OXAZIN 4 YL]PENTANOATE ACETATE; FIBRINOGEN RECEPTOR ANTAGONIST; SKN 191; SMA 101; SMA 104; SMA 179; TIROFIBAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; IC 50; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 35648995509     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.318     Document Type: Article

References (29)

1. Zablocki JA, Rico JG, Garland RB, Rogers TE, Williams K, Schretzman LA, et al. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J Med Chem 1995;38:2378-94.
2. Andronati SA, Karaseva TL, Krysko AA. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr Med Chem 2004;11:1183-211.
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
4. Ruef J, Katus HA. New antithrombotic drugs on the horizon. Expert Opin Investig Drugs 2003;12:781-97.
5. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
6. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-8.
7. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-15.
8. Kundu S, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Charcterization of an in vitro platelet function analyser, PFA-100. Clin Appl Thromb Hemost 1996;2:241-9.
9. Feuring M, Haseroth K, Janson CP, Falkenstein E, Schmidt BM, Wehling M. Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100). Int J Clin Pharmacol Ther 1999;37:584-8.
10. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995;21(Suppl 2):106-12.
11. Anderluh M, Cesar J, Stefanic P, Kikelj D, Janes D, Murn J, et al. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study. Eur J Med Chem 2005;40:25-49.
12. Copeland BE. Standard deviation; a practical means for the measurement and control of the precision of clinical laboratory determinations. Am J Clin Pathol 1957;27:551-8.
13. Watala C, Golanski J, Rozalski M, Boncler MA, Luzak B, Baraniak J, et al. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb Res 2003;109:299-306.
14. Hezard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002;108:43-7.
15. Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001;141:226-33.
16. Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002;13:277-81.
17. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B. Using the platelet function analyzer-100 for monitoring aspirin therapy. Thromb Res 2007;120:161-72.
18. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-9.
19. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999;5:122-30.
20. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620-5.
21. Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost 1999;82:1307-11.
22. Hezard N, Metz D, Nazeyrollas P, Nguyen P, Simon G, Daliphard S, et al. Free and total platelet glycoprotein IIb/IIIa measurement in whole blood by quantitative flow cytometry during and after infusion of c7E3 Fab in patients undergoing PTCA. Thromb Haemost 1999;81:869-73.
23. Lepantalo A, Beer JH, Siljander P, Syrjala M, Lassila R. Variability in platelet responses to collagen - comparison between whole blood perfusions, traditional platelet function tests and PFA-100. Thromb Res 2001;103:123-33.
24. Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin Chem Lab Med 2004;42:25-9.
25. Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, et al. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 2001;102:39-48.
26. Proimos G. Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombolysis 2001;11:99-110.
27. 2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539-43.
28. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, et al. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994;71:95-102.
29. D'Souza SE, Haas TA, Piotrowicz RS, Byers-Ward V, McGrath DE, Soule HR, et al. Ligand and cation binding are dual functions of a discrete segment of the integrin β3 subunit: cation displacement is involved in ligand binding. Cell 1994;79:659-67.